Effects of laparoscopic operation combined neoadjuvant chemotherapy on serum levels of CEA, CA242, CA19-9, CA724, ICAM-1 and VCAM-1 in patients with colorectal carcinoma

摘要

Objective: To observe the effects of neoadjuvant chemotherapy on the basis of laparoscopicoperation on colorectal carcinoma patients, serum CEA, CA242, CA19-9, CA724, ICAM-1and VCAM-1 levels. Methods: A total of 120 cases of colorectal carcinoma in our hospitalfrom January 2012 to January 2015 were retrospectively analyzed and divided into controlgroup and observation group, with each group of 60 patients. All patients were givenlaparoscopic operation, the patients in the observation group were given neoadjuvantchemotherapy (FOLFOX4 regimen) four cycles before laparoscopic surgery, fasting venousblood before and after treatment in the morning was taken and centrifuged, and the serumCA242, CA19-9, ICAM-1 and VCAM-1 levels were measured by ELISA, and the serum CEAlevels were measured by MEIA, and the serum CA724 levels were measured by ECLI, andcompared with those of the two groups. Results: (1) Before treatment, there was no statisticallysignificant difference in the serum CEA, CA242, CA19-9 and CA724 levels between the twogroups. After treatment, compared with the same group before treatment, the serum CEA,CA242, CA19-9 and CA724 levels of the two groups were significantly lower, and those levelsof observation group were significantly better than the control group, there was significantdifference between the two groups; (2) Before treatment, there was no statistically significantdifference in the serum ICAM-1, VCAM-1 levels between the two groups. After treatment,compared with the same group before treatment, the serum ICAM-1, VCAM-1 levels of thetwo groups were significantly lower, and those levels of observation group were significantlybetter than the control group, there was significant difference between the two groups.Conclusion: The treatment of colorectal cancer patients with neoadjuvant chemotherapycombined with laparoscopic operation can effectively reduce serum CEA, CA242, CA19-9,CA724, ICAM-1 and VCAM-1 levels, indicating that the program can regulate cancer-relatedtumor markers and the expression of relative factors, to promote the recovery of patientswith autoimmune system, ease the patient's condition, safe and reliable, worthy of clinicalapplication.